Share Market Newspaper

(Albany, New York) – 21st Sep 2026 – DelveInsight’s latest report, “Necrotizing Enterocolitis Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the Necrotizing Enterocolitis (NEC) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, treatment practices, emerging therapies, competitive intelligence, market dynamics, therapy uptake, reimbursement, pricing, and unmet medical needs through 2036.

According to DelveInsight, the Necrotizing Enterocolitis market size across the 7MM was approximately USD 30 million in 2025 and is projected to reach approximately USD 800 million by 2036, expanding at a 26% CAGR during 2026–2036. The market remains highly underserved, with no pharmaceutical therapies currently approved specifically for NEC and treatment largely centered on supportive care, nutritional management, and surgical intervention in severe cases.

Key Takeaways from the Necrotizing Enterocolitis Market

• The 7MM Necrotizing Enterocolitis market was approximately USD 30 million in 2025.
• The market is projected to reach approximately USD 800 million by 2036.
• The market is expected to expand at a 26% CAGR during 2026–2036.
• NEC is a severe and potentially life-threatening gastrointestinal emergency that primarily affects premature infants, particularly those treated in neonatal intensive care units.
• In the United States, annual NEC incidence remains approximately 3,000–5,000 cases, with recent estimates from 2024–2025 suggesting stabilization or modest decline.
• Japan has a comparatively low NEC incidence of approximately 100–200 cases annually.
• In 2025, the United States reported the highest absolute number of very low birth weight (≤1,500 g) preterm infants among the 7MM.
• There are currently no approved pharmaceutical therapies specifically for NEC, creating a substantial unmet medical need.
• The emerging pipeline includes IBP-9414, STMC-106, ST266, and Protego-PD.
• IBP-9414 from Infant Bacterial Therapeutics is the most advanced pipeline candidate and is being developed as a preventive probiotic therapy for NEC in very low birth weight infants.
• Key companies include Infant Bacterial Therapeutics, Leadiant Biosciences, Siolta Therapeutics, Noveome Biotherapeutics, and Plakous Therapeutics.

Keen to know more about the Necrotizing Enterocolitis market? Request a sample copy of the report for detailed market insights, epidemiology, treatment landscape, pipeline analysis, and competitive intelligence. https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market

Key Factors Driving the Necrotizing Enterocolitis Market

High Disease Burden in Premature Infants

Necrotizing Enterocolitis remains one of the most serious gastrointestinal emergencies affecting preterm infants. Improvements in neonatal care have increased survival among extremely premature infants, sustaining a population vulnerable to NEC and its associated complications.

NEC can progress rapidly from intestinal inflammation to ischemia, necrosis, perforation, peritonitis, sepsis, and death, creating a substantial clinical burden for neonatal intensive care units.

Significant Unmet Medical Needs

The absence of approved targeted pharmacological therapies represents one of the most important unmet needs in the NEC treatment landscape. Current management is primarily supportive, involving bowel rest, gastric decompression, broad-spectrum antibiotics, fluid and respiratory support, and total parenteral nutrition. Severe cases may require surgical intervention.

The lack of disease-modifying therapies creates opportunities for innovative treatments capable of preventing intestinal injury, modulating inflammation, or restoring healthy gut microbiota.

Growing Focus on Preventive Strategies

Because treatment options remain limited, research is increasingly focused on NEC prevention. Strategies include early exposure to colostrum and mother’s milk, optimized nutritional practices, probiotic supplementation, environmental control, and skin-to-skin care.

Microbiome modulation is receiving particular attention, with pharmaceutical-grade probiotics and live biotherapeutic products being investigated as potential approaches for reducing NEC risk.

Increasing Interest in Microbiome-based Therapies

Abnormal bacterial colonization and intestinal immaturity are important contributors to NEC pathogenesis. Consequently, therapies designed to influence the neonatal microbiome represent an emerging area of research.

IBP-9414, which contains Lactobacillus reuteri, is being developed as a pharmaceutical-grade probiotic intended to promote healthy gastrointestinal development and prevent NEC and sepsis in premature infants.

Advancing Clinical Pipeline

The NEC therapeutic pipeline is beginning to diversify beyond conventional supportive care. Late-stage and early-stage candidates are exploring probiotic, live biotherapeutic, regenerative, anti-inflammatory, and immunomodulatory approaches.

The advancement of these candidates could significantly alter the NEC market if clinical and regulatory milestones are successfully achieved.

Competitive Landscape

The NEC market remains relatively concentrated because no pharmaceutical therapy is currently approved specifically for the disease. Key companies identified by DelveInsight include:

• Infant Bacterial Therapeutics
• Leadiant Biosciences
• Siolta Therapeutics
• Noveome Biotherapeutics
• Plakous Therapeutics

Key emerging therapies include:

• IBP-9414 – Infant Bacterial Therapeutics
• STMC-106 – Siolta Therapeutics
• ST266 – Noveome Biotherapeutics
• Protego-PD – Plakous Therapeutics

Among these candidates, IBP-9414 is the most advanced program, with the company pursuing a registration-enabling development pathway following Phase III clinical evaluation in very low birth weight infants.

Recent Developments in the Necrotizing Enterocolitis Market

• March 2026: Noveome Biotherapeutics announced that the independent Data Safety Monitoring Board completed its review of safety data from Cohort 1 of the clinical trial evaluating ST266 for NEC in neonates.
• March 2026: Infant Bacterial Therapeutics announced publication of results from its pivotal Phase III trial of IBP-9414 in very low birth weight infants, known as the Connection Study, in Pediatric Research, a Nature publication.
• December 2025: Infant Bacterial Therapeutics announced a partnership with BioConnection for production of the IBP-9414 drug product.
• November 2025: Infant Bacterial Therapeutics announced its decision to pursue an accelerated approval pathway for IBP-9414.

What is Necrotizing Enterocolitis?

Necrotizing Enterocolitis is a severe, potentially life-threatening gastrointestinal disease that predominantly affects premature infants. It is characterized by intestinal inflammation, bacterial invasion, progressive tissue injury, and necrosis. In severe cases, intestinal perforation can lead to peritonitis, sepsis, and death.

The exact cause of NEC remains incompletely understood. However, intestinal immaturity, abnormal gut bacterial colonization, exaggerated inflammatory responses, and nutritional factors are considered important contributors to disease development.

The disease may progress from intestinal inflammation to ischemia, necrosis, and perforation. Clinical symptoms can include poor feeding, vomiting, abdominal distension or tenderness, lethargy, and apnea. Diagnosis generally involves clinical evaluation, laboratory testing, and imaging such as abdominal X-rays.

Inflammatory and immunological pathways, particularly the balance between TLR4 and TLR9 signaling, have also been implicated in NEC pathogenesis.

Current Treatment Landscape

There are currently no pharmaceutical therapies approved specifically for Necrotizing Enterocolitis. Treatment is primarily determined by disease severity and focuses on stabilization and preventing further intestinal injury.

For early-stage disease, management generally involves:

• Bowel rest
• Gastric decompression
• Broad-spectrum antibiotics
• Fluid resuscitation
• Respiratory and cardiovascular support
• Total parenteral nutrition
• Close clinical monitoring

Advanced or non-responsive disease may require surgical intervention, including laparotomy, removal of necrotic bowel, ostomy, or peritoneal drainage in critically ill infants.

With limited treatment options, preventive strategies are increasingly emphasized. These include mother’s milk and colostrum feeding, optimized nutrition, probiotic use, environmental protection, and skin-to-skin care.

However, probiotic use remains inconsistent because of the lack of standardized formulations, safety considerations, and the absence of FDA-approved pharmaceutical-grade probiotic products specifically for NEC.

Necrotizing Enterocolitis Epidemiology

DelveInsight’s epidemiological assessment covers the 7MM and focuses on the burden of NEC among premature infants, particularly those with very low birth weight.

Key epidemiological findings include:

• The United States had the highest absolute number of very low birth weight preterm infants (≤1,500 g) among the 7MM in 2025.
• The incidence of preterm infants with birth weight ≤1,500 g is anticipated to increase during the forecast period.
• Across the 7MM, the population of preterm infants weighing ≤1,500 g is expected to remain stable to slightly increasing through 2030.
• NEC incidence in high-income regions, including the US, EU4, and UK, has stabilized or modestly declined by 2025.
• The United States has an annual NEC incidence of approximately 3,000–5,000 cases.
• Germany reported the highest number of very low birth weight preterm infants among the EU4, followed by France.
• Japan has an annual NEC incidence of approximately 100–200 cases.

Epidemiology Segmentation

DelveInsight segments the NEC epidemiology analysis into:

• Total incident cases of preterm infants by birth weight (≤1,500 g)
• Total incident cases of Necrotizing Enterocolitis

Unmet Needs in Necrotizing Enterocolitis

Despite advances in neonatal care, significant unmet needs remain:

1. Lack of noninvasive and targeted treatment options
2. Challenges associated with early diagnosis
3. High mortality and morbidity
4. Reduced quality of life and long-term complications
5. Incomplete understanding of disease etiology
6. Need for effective preventive strategies
7. Lack of standardized probiotic approaches

These unmet needs provide opportunities for therapies capable of preventing NEC, improving early diagnosis, reducing disease severity, and minimizing the need for surgical intervention.

Scope of the Necrotizing Enterocolitis Market Report

• Study Period: 2022–2036
• Historical Period: 2022–2025
• Forecast Period: 2026–2036
• Base Year: 2026
• Geographies: US, Germany, France, Italy, Spain, UK, and Japan
• 7MM Market Size, 2025: ~USD 30 million
• Projected Market Size, 2036: ~USD 800 million
• Market CAGR: 26% during 2026–2036
• Epidemiology Segmentation: Total incident cases of preterm infants by birth weight (≤1,500 g) and total incident cases of NEC
• Market Segmentation: Region/geographies and drugs/therapies
• Key Companies: Infant Bacterial Therapeutics, Leadiant Biosciences, Siolta Therapeutics, Noveome Biotherapeutics, Plakous Therapeutics
• Key Emerging Therapies: IBP-9414, STMC-106, ST266, Protego-PD, and others
• Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs
• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden trends, treatment addressable market, competitive landscape, company insights, pricing and analogue assessment, therapy adoption/uptake, and peak patient share analysis.

To Know More About the Necrotizing Enterocolitis Market Report

Necrotizing Enterocolitis Market Insight, Epidemiology and Market Forecast – 2036

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of Necrotizing Enterocolitis
6. Necrotizing Enterocolitis Market Overview
7. Disease Overview
8. Causes, Risk Factors, Signs and Symptoms
9. Pathogenesis and Diagnosis
10. Treatment Landscape
11. Current Treatment Practices
12. Epidemiology and Patient Burden
13. Patient Journey
14. Emerging Therapies and Pipeline Analysis
15. Competitive Landscape
16. Drug Uptake and Patient Share
17. Market Size and Forecast
18. Market Drivers and Barriers
19. Unmet Medical Needs
20. Market Access and Reimbursement
21. Pricing and Analogue Assessment
22. KOL and SME Insights
23. SWOT and Conjoint Analysis
24. Regional Market Analysis
25. Company and Therapy Profiles
26. Market Outlook
27. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services